S&P 500   5,199.06
DOW   38,459.08
QQQ   445.37
Fastenal, CarMax fall; Alpine Immune Sciences, Arvinas rise, Thursday, 4/11/2024
Stock market today: Global markets mixed after Wall St rebound led by Big Tech
Dividend Aristocrat Fastenal Goes on Sale: Buy It While It’s Down
How major US stock indexes fared Thursday, 4/11/2024
Closing prices for crude oil, gold and other commodities
Carmax Returns to the Bargain Basement: Buy the Dip? 
Homebuyers’ quandary: to wait or not to wait for lower mortgage rates
S&P 500   5,199.06
DOW   38,459.08
QQQ   445.37
Fastenal, CarMax fall; Alpine Immune Sciences, Arvinas rise, Thursday, 4/11/2024
Stock market today: Global markets mixed after Wall St rebound led by Big Tech
Dividend Aristocrat Fastenal Goes on Sale: Buy It While It’s Down
How major US stock indexes fared Thursday, 4/11/2024
Closing prices for crude oil, gold and other commodities
Carmax Returns to the Bargain Basement: Buy the Dip? 
Homebuyers’ quandary: to wait or not to wait for lower mortgage rates
S&P 500   5,199.06
DOW   38,459.08
QQQ   445.37
Fastenal, CarMax fall; Alpine Immune Sciences, Arvinas rise, Thursday, 4/11/2024
Stock market today: Global markets mixed after Wall St rebound led by Big Tech
Dividend Aristocrat Fastenal Goes on Sale: Buy It While It’s Down
How major US stock indexes fared Thursday, 4/11/2024
Closing prices for crude oil, gold and other commodities
Carmax Returns to the Bargain Basement: Buy the Dip? 
Homebuyers’ quandary: to wait or not to wait for lower mortgage rates
S&P 500   5,199.06
DOW   38,459.08
QQQ   445.37
Fastenal, CarMax fall; Alpine Immune Sciences, Arvinas rise, Thursday, 4/11/2024
Stock market today: Global markets mixed after Wall St rebound led by Big Tech
Dividend Aristocrat Fastenal Goes on Sale: Buy It While It’s Down
How major US stock indexes fared Thursday, 4/11/2024
Closing prices for crude oil, gold and other commodities
Carmax Returns to the Bargain Basement: Buy the Dip? 
Homebuyers’ quandary: to wait or not to wait for lower mortgage rates
NASDAQ:CCCC

C4 Therapeutics (CCCC) Stock Price, News & Analysis

$7.79
+0.07 (+0.91%)
(As of 04/11/2024 ET)
Today's Range
$7.53
$7.92
50-Day Range
$5.30
$11.00
52-Week Range
$1.06
$11.88
Volume
862,310 shs
Average Volume
2.12 million shs
Market Capitalization
$534.39 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$10.25

C4 Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.50 Rating Score
Upside/​Downside
31.6% Upside
$10.25 Price Target
Short Interest
Bearish
13.34% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.05mentions of C4 Therapeutics in the last 14 days
Based on 9 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($1.86) to ($2.07) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.08 out of 5 stars

Medical Sector

2434th out of 2,787 stocks

Biological Products, Except Diagnostic Industry

391st out of 450 stocks

CCCC stock logo

About C4 Therapeutics Stock (NASDAQ:CCCC)

C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma, currently under Phase 1/2 clinical trials. The company is also developing CFT1946, an orally bioavailable BiDAC degrader targeting V600X mutant BRAF to treat melanoma, non-small cell lung cancer (NSCLC), colorectal cancer, and other solid malignancies, currently under Phase 1/2 clinical trials; and CFT8919, an orally bioavailable, allosteric, and mutant-selective BiDAC degrader of epidermal growth factor receptor, or EGFR, with an L858R mutation in NSCLC. It has strategic collaborations with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; Biogen MA, Inc.; Betta Pharmaceuticals, Co., Ltd.; and Merck Sharp & Dohme, LLC, as well as Calico Life Sciences LLC. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.

CCCC Stock Price History

CCCC Stock News Headlines

C4 Therapeutics (NASDAQ:CCCC) Shares Gap Down to $7.97
Analysts Predict Price Tag for Gold to TRIPLE
Due to both domestic and global issues, the trajectory of this precious metal could skyrocket in the coming months… Which is why billionaires and Central Banks alike are scooping up gold at record rates!
C4 Dips on Release of Data
Analysts Predict Price Tag for Gold to TRIPLE
Due to both domestic and global issues, the trajectory of this precious metal could skyrocket in the coming months… Which is why billionaires and Central Banks alike are scooping up gold at record rates!
CCCC Mar 2024 17.000 call
CCCC Mar 2024 10.000 put
Guru Fundamental Report for CCCC
CCCC Mar 2024 9.000 call
Breaking Down C4 Therapeutics: 4 Analysts Share Their Views
CCCC Mar 2024 8.500 put
CCCC Mar 2024 7.000 put
C4 Therapeutics price target raised by $1 at Stifel, here's why
C4 Therapeutics Stock (NASDAQ:CCCC) Insider Trades
See More Headlines
Receive CCCC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for C4 Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/22/2024
Today
4/11/2024
Next Earnings (Estimated)
5/02/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:CCCC
Fax
N/A
Employees
145
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$10.25
High Stock Price Target
$20.00
Low Stock Price Target
$2.00
Potential Upside/Downside
+31.6%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
6 Analysts

Profitability

Net Income
$-132,490,000.00
Net Margins
-638.34%
Pretax Margin
-632.17%

Debt

Sales & Book Value

Annual Sales
$20.76 million
Book Value
$4.07 per share

Miscellaneous

Free Float
63,134,000
Market Cap
$534.39 million
Optionable
Optionable
Beta
3.18
10 "Recession Proof" Stocks That Will Thrive in Any Market Cover

Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Key Executives

  • Mr. Andrew J. Hirsch M.B.A. (Age 53)
    CEO, President & Director
    Comp: $971k
  • Dr. Kenneth C. Anderson M.D. (Age 73)
    Ph.D., Co-Founder, Independent Director & Member of Scientific Advisory Board
    Comp: $39.03k
  • Dr. Stewart FisherDr. Stewart Fisher (Age 57)
    Chief Scientific Officer
    Comp: $657.34k
  • Mr. Scott N. Boyle M.B.A. (Age 46)
    Ph.D., Chief Business Officer
    Comp: $672.78k
  • Dr. Nathanael S. Gray Ph.D.
    Co-Founder & Member of Scientific Advisory Board
  • Ms. Kendra Adams
    Chief Financial Officer
  • Mr. Mark Mossler (Age 51)
    Chief Accounting Officer
  • Ms. Jolie M. Siegel J.D. (Age 47)
    Chief Legal Officer & Corporate Secretary
    Comp: $610.4k
  • Ms. Kelly A. Schick (Age 44)
    Chief People Officer
  • Dr. Isabel Chiu Ph.D.
    Senior Vice President of Strategic Alliances & Business Development

CCCC Stock Analysis - Frequently Asked Questions

Should I buy or sell C4 Therapeutics stock right now?

6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for C4 Therapeutics in the last twelve months. There are currently 3 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" CCCC shares.
View CCCC analyst ratings
or view top-rated stocks.

What is C4 Therapeutics' stock price target for 2024?

6 Wall Street analysts have issued 1 year price targets for C4 Therapeutics' stock. Their CCCC share price targets range from $2.00 to $20.00. On average, they expect the company's stock price to reach $10.25 in the next twelve months. This suggests a possible upside of 31.6% from the stock's current price.
View analysts price targets for CCCC
or view top-rated stocks among Wall Street analysts.

How have CCCC shares performed in 2024?

C4 Therapeutics' stock was trading at $5.65 at the beginning of 2024. Since then, CCCC shares have increased by 37.9% and is now trading at $7.79.
View the best growth stocks for 2024 here
.

Are investors shorting C4 Therapeutics?

C4 Therapeutics saw a increase in short interest in the month of March. As of March 31st, there was short interest totaling 9,150,000 shares, an increase of 73.0% from the March 15th total of 5,290,000 shares. Based on an average trading volume of 3,740,000 shares, the short-interest ratio is presently 2.4 days.
View C4 Therapeutics' Short Interest
.

When is C4 Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024.
View our CCCC earnings forecast
.

How were C4 Therapeutics' earnings last quarter?

C4 Therapeutics, Inc. (NASDAQ:CCCC) posted its quarterly earnings data on Thursday, February, 22nd. The company reported ($0.68) earnings per share for the quarter, missing analysts' consensus estimates of ($0.67) by $0.01. The firm earned $3.26 million during the quarter, compared to analyst estimates of $5.23 million. C4 Therapeutics had a negative trailing twelve-month return on equity of 55.30% and a negative net margin of 638.34%.

What ETF holds C4 Therapeutics' stock?

Harbor Disruptive Innovation ETF holds 31,984 shares of CCCC stock, representing 0.70% of its portfolio.

When did C4 Therapeutics IPO?

C4 Therapeutics (CCCC) raised $150 million in an IPO on Friday, October 2nd 2020. The company issued 8,800,000 shares at $16.00-$18.00 per share. Jefferies, Evercore ISI, BMO Capital Markets and UBS Investment Bank acted as the underwriters for the IPO.

How do I buy shares of C4 Therapeutics?

Shares of CCCC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:CCCC) was last updated on 4/12/2024 by MarketBeat.com Staff

From Our Partners